Novavax, the Maryland-anchored vaccine developer, is set to launch a large Phase 3 study of its vaccine candidate in the U.S. and Mexico.
↧
Novavax, the Maryland-anchored vaccine developer, is set to launch a large Phase 3 study of its vaccine candidate in the U.S. and Mexico.